Immuneering (IMRX) Consolidated Net Income (2020 - 2026)

Immuneering's Consolidated Net Income history runs 7 years deep, the most recent figure standing at -$14.0 million for Q1 2026.

• In Q1 2026, Consolidated Net Income rose 7.12% year-over-year to -$14.0 million; the TTM figure through Mar 2026 stood at -$55.3 million (up 10.87% YoY), while the FY2025 annual figure was -$56.3 million, up 8.36% from the prior year.
• Consolidated Net Income was -$14.0 million for Q1 2026 at Immuneering, down from -$11.9 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$11.5 million in Q2 2022 to a low of -$18.1 million in Q4 2024.
• Historically, Consolidated Net Income has averaged -$14.0 million across 5 years, with a median of -$14.0 million in 2026.
• The sharpest annual moves came in 2022 and 2025: Consolidated Net Income tumbled 105.36% in 2022, then soared 34.46% in 2025.
• A 5-year view of Consolidated Net Income shows it stood at -$13.5 million in 2022, then declined by 15.44% to -$15.5 million in 2023, then retreated by 16.69% to -$18.1 million in 2024, then surged by 34.46% to -$11.9 million in 2025, then decreased by 17.52% to -$14.0 million in 2026.
• The last three Consolidated Net Income figures came in at -$14.0 million (Q1 2026), -$11.9 million (Q4 2025), and -$15.0 million (Q3 2025), per Business Quant data.